Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro

Journal of Pharmacology and Experimental Therapeutics

Volumn 297, Issue 1, 2001, Pages 267-279

  Hatzelmann, A ^a   Schudt, C ^a  

^a ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 CYCLOPROPYLMETHOXY 4 DIFLUOROMETHOXY N [3,4 DICHLOROPYRID 4 YL] BENZAMIDE; BENZAMIDE DERIVATIVE; CILOMILAST; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROFLUMILAST; ROLIPRAM; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; EFFECTOR CELL; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; NEUTROPHIL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMINOPYRIDINES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZAMIDES; CD4-POSITIVE T-LYMPHOCYTES; CHEMILUMINESCENT MEASUREMENTS; CYCLOPROPANES; CYTOKINES; DENDRITIC CELLS; EOSINOPHILS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MONOCYTES; NEUTROPHILS; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035084103     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
2. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)
3. SB207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions
4. An improved assay of cyclic 3′,5′-nucleotide phosphodiesterase with QAE Sephadex A-25
5. Multiple cyclic nucleotide phosphodiesterases
6. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor
7. Molecular aspects of inhibitor interaction with PDE4
8. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
9. In vitro differentiation of human monocytes to macrophages: Change of PDE profile and its relationship to suppression of tumour necrosis factor-α by PDE inhibitors
10. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function
11. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: A comparative study
12. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?
13. 2--transport ATPase and brain phosphodiesterase by activators and inhibitors
14. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds
15. Involvement of calcium in the thimerosal-stimulated formation of leukotriene by fMLP in human polymorpho-nuclear leukocytes
16. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions
17. Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuelear leukocytes
18. Regulation of immunologic homeostasis in peripheral tissues by dendritic cells: The respiratory tract as a paradigm
19. Anti-inflammatory effects of the novel phosphodiesterase IV inhibitor RP 73401
20. Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods
21. Therapeutic potential and strategies for inhibiting tumor necrosis factor-α
22. 2-inhibitory effects in human neutrophils
23. Immunological/physiological relationships in asthma: Potential regulation by lung macrophages
24. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways
25. The role of lymphocytes in allergic disease
26. Proliferating dendritic cell progenitors in human blood
27. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
28. Stereospecific binding of the antidepressant rolipram to brain protein structures
29. Therapeutic potential of selective PDE inhibitors in asthma
30. i
31. Zardaverine as a selective inhibitor of phosphodiesterase isozymes
32. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
33. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a "low-affinity" phosphodiesterase 4 conformer
34. 4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects
35. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages
36. Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods
37. Phosphodiesterases in asthma
38. Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future?
39. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme
40. Phosphodiesterase isozymes - Molecular targets for novel anti-asthma agents